CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 14 enrolled
Drug / intervention
Daytrana (methylphenidate patch)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00780208
NCT00780208N/ACompleted
CompareCT.gov

The Evaluation of the Safety and Efficacy of the Methylphenidate Patch in Former Stimulant Users With ADHD

Medical University of South Carolina·interventional·Posted Oct 27, 2008·Updated Jun 14, 2018

In Brief

A clinical study evaluating Daytrana (methylphenidate patch) for Adult Attention Deficit Hyperactivity Disorder (ADHD). Completed, enrolled 14 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the effectiveness and safety of Daytrana® in the treatment of attention deficit hyperactivity disorder (ADHD) in adults who have abused stimulants in the past. Daytrana® is a stimulant medication that has been approved by the Food and Drug Administration for the treatment of ADHD in children over the age of 6 years old.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Attention Deficit Hyperactivity Disorder (ADHD)
CountriesUnited States
CollaboratorsShire

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 27, 2008
Enrollment StartApr 1, 2007
Primary CompletionOct 1, 2008
Study CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 17.7 years ago

Interventions

Daytrana (methylphenidate patch)drug

Subjects will be provided with a 7-day supply of medication at each study visit. The dose will be flexible and will be titrated based on effect and tolerability. Unless a subject is experiencing side effects, the dose will be increased if a 25% reduction in ADHD symptoms as determined by the WRAADDS is not obtained. A proposed dosing schedule is as follows: Week 1: 12.5 cm2, Week 2: 18.75 cm2, Week 3: 25 cm2, Week 4: 37.5 cm2. The dose may be decreased as needed for tolerability.